Privia Health Acquires Evolent's ACO Division
Privia Health Group, Inc. (NASDAQ: PRVA) has recently made a strategic decision to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE: EVH). This acquisition represents a significant step forward for Privia as it aims to expand its footprint in the growing value-based care sector.
Financial Details of the Acquisition
Privia Health plans to complete the acquisition with an initial payment of $100 million in cash. Furthermore, there is potential for an additional $13 million payment based on performance metrics linked to the Medicare Shared Savings Program, depending on results from the year 2025.
Timeline for Closing the Transaction
The acquisition is expected to conclude in the fourth quarter of 2025. At this point, it is forecasted to have a favorable impact on Privia’s Adjusted EBITDA starting in 2026.
Impact on Attributed Lives
The ACO business that Privia is acquiring currently manages care for over 120,000 attributed lives within the Medicare Shared Savings Program and various commercial and Medicare Advantage programs. Following this transaction, the company will serve approximately 1.5 million lives under value-based care arrangements, spanning commercial, Medicare, Medicare Advantage, and Medicaid.
Strategic Benefits and Future Outlook
By acquiring Evolent’s ACO business, Privia Health will not only increase its volume of attributed lives in states where it already operates but also penetrate new geographical markets. This move creates significant synergy opportunities for ACO-participating providers to integrate with Privia’s Medical Groups, enhancing service offerings and technology capabilities.
Market Reaction
Following the announcement of the acquisition, Evolent Health's stock witnessed a notable increase, reflecting investor confidence. As of the last check, shares of EVH were up by 12.60%, trading at $9.45. Meanwhile, PRVA shares rose by 1.15%, priced at $23.71.
Analysts Weigh In
Analysts from William Blair provided insights into the strategic importance of this deal for Privia. They emphasized that the acquisition enhances Privia’s existing capabilities and expands its capacity in value-based care significantly. The transaction offers an opportunity for Evolent’s ACO-participating providers to join Privia’s wide-ranging services and technology solutions.
Performance Expectations
Even without the impact of this acquisition, Evolent reaffirmed its third-quarter guidance for 2025, with expected revenue ranging from $460 million to $480 million, marginally below market consensus. They also confirmed a similar outlook for the full year, projecting revenue between $1.85 billion to $1.88 billion with adjusted EBITDA anticipated between $140 million to $165 million.
Frequently Asked Questions
What prompted Privia to acquire Evolent's ACO business?
The acquisition is part of Privia's strategy to enhance its capabilities in value-based care and expand its footprint across more regions.
How much is Privia paying for the acquisition?
Privia will pay $100 million upfront, with the possibility of an additional $13 million based on performance metrics in 2025.
When is the acquisition expected to close?
The transaction is anticipated to close in the fourth quarter of 2025.
What impact will this acquisition have on Privia’s attributed lives?
Post-acquisition, Privia is expected to manage approximately 1.5 million attributed lives under various value-based care arrangements.
How did the market react to this acquisition announcement?
Following the news, shares of Evolent Health increased by 12.60%, while Privia Health experienced a modest rise of 1.15%.
